Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17952879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transplant Center Quality Assessment Using a Continuously Updatable, Risk‐Adjusted Technique (CUSUM)

  2006cited by this paper
• Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation

  2006cited by this paper
• Cumulative risk adjusted monitoring of 30-day mortality after cardiothoracic transplantation: UK experience.

  2005cited by this paper
• A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.

  2005cited by this paper
• Use of risk-adjusted CUSUM and RSPRTcharts for monitoring in medical contexts

  2003cited by this paper
• Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients

  2003cited by this paper
• Effect of Off‐Pump Coronary Artery Bypass Grafting on Risk‐Adjusted and Cumulative Sum Failure Outcomes After Coronary Artery Surgery

  2002cited by this paper
• Hepatic Venoocclusive Disease in Blood and Bone Marrow Transplantation in Children and Young Adults: Incidence, Risk Factors, and Outcome in a Cohort of 241 Patients

  2002cited by this paper
• THERAPEUTIC MONITORING OF BUSULFAN IN PEDIATRIC BONE MARROW TRANSPLANTATION

  2002cited by this paper
• Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

  2002cited by this paper
• Risk-Adjusted Monitoring of Binary Surgical Outcomes

  2001cited by this paper
• Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

  2001cited by this paper
• Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

  2001cited by this paper
• Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies

  2000cited by this paper
• Monitoring surgical performance using risk-adjusted cumulative sum charts.

  2000cited by this paper
• Veno‐occlusive disease of the liver after hemopoietic cell transplantation

  2000cited by this paper
• Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma.

  2000cited by this paper
• Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/ cyclophosphamide vs total body irradiation: a meta-analysis

  1998cited by this paper
• Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.

  1998cited by this paper
• Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors

  1998cited by this paper
• Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics

  1998cited by this paper
• Ursodiol to prevent hepatic venoocclusive disease.

  1997cited by this paper
• Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation

  1997cited by this paper
• Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.

  1996cited by this paper
• Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.

  1995cited by this paper
• Veno-occlusive disease of the liver complicating bone marrow transplantation.

  1994cited by this paper
• Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients

  1993cited by this paper
• Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

  1993cited by this paper
• Busulfan disposition in children.

  1990cited by this paper
• The hidden effect of time.

  1988cited by this paper
• Optimal sampling times for pharmacokinetic experiments

  1981cited by this paper

• Tandem high‐dose chemotherapy with autologous stem cell rescue for stage M high‐risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens

  2020cites this paper
• Personalised dosing of vancomycin: A prospective and retrospective comparative quasi‐experimental study

  2020cites this paper
• Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure

  2018cites this paper
• Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment.

  2016cites this paper
• Phase II study of dose‐modified busulfan by real‐time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy

  2012cites this paper
• Hepatic Veno-Occlusive Disease

  2010cites this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cites this paper
• Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

  2010cites this paper
• Busulfan in hematopoietic stem cell transplant setting

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper
• Therapeutic drug monitoring of busulfan in transplantation.

  2008cites this paper